| ••• | Please type a plus sign (+) inside this box -> | 1 |
|-----|--|---|
| | | |

| | | | | Complete if Known | | | |
|-------------------|--------------------|------------------------|----------|----------------------|-------------------|--|--|
| Substitute for fo | rm 1449A/B/PTO | | | Application Number | Unassigned | | |
| INEC | RMATION I | חופר | NOUDE | Filing Date | Herewith | | |
| | | | | First Named Inventor | Shanker Lal GUPTA | | |
| STA | TEMENT BY | AP | PLICANI | Group Art Unit | Unassigned | | |
| 1 | (Use as many sheet | s as ne | cessary) | Examiner Name | Unassigned | | |
| Sheet 1 of 2 | | Attorney Docket Number | 224397 | | | | |

| | | | | | U.S. PATENT DOCUMENTS | | |
|----------------------|----|----------------------|---------------------------------|-----------|-------------------------------|---------------------|-------------------------------|
| | | U.S. Patent Document | | | | | |
| Examiner Initials | | Doc. No. | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Filing Date If Appropriate |
| M·c·Ht | | AA | 4,499,082 | | Shenvi et al. | 2/12/85 | |
| | | AB | 5,106,948 | | Kinder et al. | 4/21/92 | |
| 1 | | AC | 5,169,841 | | Kleeman et al. | 12/8/92 | |
| | | AD | 5,187,157 | | Kettner et al. | 2/16/93 | |
| | | AE | 5,242,904 | | Kettner et al. | 9/7/93 | |
| | | | 5,250,720 | | Kettner et al. | 10/5/93 | |
| | | AG | 5,492,900 | | LaHann | 2/20/96 | |
| | | AH | 5,574,017 | | Gutheil | 11/12/96 | |
| | | AI | 5,780,454 | | Adams et al. | 7/14/98 | |
| | | AJ | 5,935,944 | | LaHann | 8/10/99 | T |
| | | AK | 5,990,083 | | Iqbal et al. | 11/23/99 | |
| - | | AL | 6,066,730 | | Adams et al. | 5/23/00 | |
| | | AM | 6,083,903 | | Adams et al. | 7/4/00 | |
| | | AN | 6,619,076 | | Shull et al. | 1/2/01 | |
| | | AO | 6,297,217 | | Adams et al. | 10/2/01 | |
| | | AP | 2002/0169114 | A1 | Gupta | 11/14/02 | |
| MC | ·H | AQ | 2002/0188100 | A1 | Plamondon et al. | 12/12/02 | 1 |

| | | | | FORE | IGN PATENT DOCUMENTS | | | |
|----------------------|-------------|--------|---------------------------------|--------------|----------------------------------|---------------------|-------------|------|
| | | F | oreign Patent Docume | nt | | | Translation | |
| Examiner Initials | Doc. No. | Office | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Yes | No*+ |
| M-C.H | AR | wo | 98/35691 | A1 | Proscript, Inc. | 8/20/98 | | |
| 7 | AS | wo | 99/15183 | A1 | Proscript Inc. | 4/1/99 | | |
| | AT | wo | 00/57887 | A1 | Glycosyn Pharmaceuticals, Inc. | 10/5/00 | | |
| | AÜ | wo | 01/02424 | A2 | DuPont Pharmaceuticals Co. | 1/11/01 | | |
| | AV | wo | 02/059130 | A1 | U.S. Government | 1/8/02 | | |
| WC+1 | AW | wo | 02/059131 | A1 | Millennium Pharmaceuticals, Inc. | 8/1/02 | | |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | | | | |
|----------|--|--|-----|------|--|--|
| Examiner | Doc. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item | | | | | |
| Initials | No. | (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Yes | No*+ | | |
| MC+H | AX | CIECHANOVER, "The Ubiquitin-Proteasome Proteolytic Pathway," <i>Cell</i> , Vol. 79, pp. 13-21 (October 7, 1994) | | | | |
| m(.H | ΑΥ | GENNARO, "Remington: The Science and Practice of Pharmacy," 20 th Edition, Chapter 42, pp. 802-803 (2000) | | | | |

| | | | | | 1 |
|--------------------|-----|-----------------|----|----|----|
| Examiner Signature | 14C | Date Considered | 5/ | 25 | 05 |

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

| Please type a plus sign (+) inside this box> | Ŧ |
|--|---|
|--|---|

| | | | | Complet if Known | | | |
|------------------------|--------------------|---------|----------|------------------------|-------------------|--|--|
| Substitute for fo | m 1449A/B/PTO | | | Application Number | Unassigned | | |
| 15156 | SOMETION | | N OCUPE | Filing Date | Herewith | | |
| | DRMATION I | | | First Named Inventor | Shanker Lal GUPTA | | |
| STATEMENT BY APPLICANT | | | | Group Art Unit | Unassigned | | |
| | (Use as many sheet | s as na | CARSSAC) | Examiner Name | Unassigned | | |
| Sheet 2 of 2 | | | 2 | Attorney Docket Number | 224397 | | |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | - | 1-4' |
|-------------------|-------------|---|-----|------|
| Examiner Initials | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Yes | No** |
| Mc.H | ΑZ | Kataoka et al., "Totally Synthetic Polymer Gels Responding to External Glucose Concentration: Their Preparation and Application to On-Off Regulations of Insulin Release," <i>J. Am. Chem. Soc.</i> , 120:12694-12695 (1998) | | |
| | ВА | KIBBE, "Handbook of Pharmaceutical Excipients," 3rd Edition, pp. 324-328 (2000) | | |
| | ВВ | KORCEK et al., "Absolute Rate Constants for the Autoxidation of Organometallic Compounds, Part II. Benzylboranes and 1-Phenylethylboranes," <i>J. Chem. Soc., Perkin Trans.</i> II, pp. 242-248 (1972) | | |
| | ВС | RICHARDSON et al., "A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma," N. Engl. J. Med., Vol. 348, No. 26, pp. 2609-2617 (June 2003) | | |
| | BD | SNYDER et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," J. Am. Chem. Soc., 80, pp. 3611-3615 (1958) | | |
| | BE | STELLA et al., "Development of Parenteral Formulations of Experimental Cytoxic Agents. I. Rhizoxin (NSC-332598)," International Journal of Pharmaceutics, Vol. 43, pp. 191-199 (1988) | | |
| | BF | WILLIAMS et al., "The Effects of Cooling Rate on Solid Phase Transitions and Associated Vial Breakage Occurring in Frozen Mannitol Solutions," <i>Journal of Parenteral Science & Technology</i> , Vol. 40, No. 4, pp. 135-141 (July-August 1986) | | |
| MicH | BG | WILLIAMS et al., "Vial Breakage by Frozen Mannitol Solutions: Correlation with Thermal Characteristics and Effect of Stereoisomerism, Additives, and Vial Configuration," Journal of Parenteral Science & Technology, Vol. 45, No. 2, pp. 94-100 (March-April 1991) | | |
| | | | | |
| | | | | |
| - | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Examiner Signature | 412 | Date Considered | 5/25 | 105 |
|--------------------|-----|-----------------|------|-------|
| | | | | 7 - " |

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).